Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer скачать в хорошем качестве

Results for Tisotumab Vedotin in Patients With Metastatic or Recurrent Cervical Cancer

David S. Hong, MD, deputy director of the department of investigational cancer therapeutics and associate vice president at The University of Texas MD Anderson Cancer Center, discusses the results from the phase II innovaTV 201 trial looking at the antibody-drug conjugate tisotumab vedotin in patients with metastatic or recurrent cervical cancer. The phase I study led to a recommended dose of 2 mg/kg every 3 weeks, according to Hong. This dose showed activity across a number of histologies, but in particular showed promising results in this patient population with cervical cancer. There was a 35% response rate as well as a progression-free survival (PFS) of 4.1 months in patients with metastatic or recurrent cervical cancer. The approved second-line pembrolizumab (Keytruda) option only has a response rate of about 14% and a PFS of 2.1 months in this population, so Hong says it is exciting to see such a high response and prolonged PFS in this patient population that has been difficult to treat. For more resources and information regarding anticancer targeted therapies in cervical cancer: http://targetedonc.com/resource-cente...